title: Effects of cyclosporin A on in vitro lymphocyte response to autologous or allogeneic stimulation: influence of HLA phenotypes.
abstract: In this study we investigated whether the interindividual variability of lymphocyte sensitivity to cyclosporin A (CsA) could be controlled by the HLA region. The models used were the in vitro primary and secondary autologous (AMLR) and allogeneic mixed lymphocyte (MLR) cultures of cells from 32 healthy subjects from our HLA reference panel. Our results show that CsA inhibited primary allogeneic MLR to a much greater extent than primary AMLR (-81 +/- 2% vs -38 +/- 8%, P less than 0.001). The same pattern was observed when cells harvested from CsA-treated primary cultures were rechallenged in secondary cultures with the original sensitizing stimulator cells (-40 +/- 6% vs -17 +/- 9%, P less than 0.05). No differences were observed in primary autologous and allogeneic cultures among responders of different HLA phenotypes. In contrast, the secondary responses did vary according to the HLA types: in secondary AMLR, CsA-priming did not lower, or even enhance, the proliferative responses of DR5+ and/or DR2+ lymphocytes (+7 +/- 13%), whereas it significantly lowered the responses of DR2-5- cells (-46 +/- 8%). In secondary MLR, lymphocytes proliferation was lowered by CsA-priming in all but DRW11(5)+ subjects (-45 +/- 7% vs +2 +/- 23%, P less than 0.05). It is concluded that the individual HLA phenotype influences the pattern of lymphocyte sensitivity to CsA.
authors.affiliation: Institute of Internal Medicine, Infectious Diseases and Immunopathology, University of Milan, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Scorza
authors.forename: M
authors.initials: M
authors.lastname: Vanoli
authors.forename: C
authors.initials: C
authors.lastname: Coppola
authors.forename: A
authors.initials: A
authors.lastname: Cigognini
authors.forename: G
authors.initials: G
authors.lastname: Fabio
authors.forename: C
authors.initials: C
authors.lastname: Zanussi
mesh_terms: D000328:Adult; D003524:Cyclosporins / Q000494:pharmacology*; D006680:HLA Antigens / Q000235:genetics*; D006684:HLA-DR Antigens / Q000235:genetics; D059810:HLA-DR Serological Subtypes; D015802:HLA-DR2 Antigen; D015805:HLA-DR5 Antigen; D006801:Humans; D066298:In Vitro Techniques; D008213:Lymphocyte Activation / Q000187:drug effects*; D007959:Lymphocyte Culture Test, Mixed; D008875:Middle Aged; D010641:Phenotype
chemical_list: D003524:Cyclosporins; D006680:HLA Antigens; D006684:HLA-DR Antigens; D059810:HLA-DR Serological Subtypes; C080766:HLA-DR11 antigen; D015802:HLA-DR2 Antigen; D015805:HLA-DR5 Antigen